Notably, compared to melanomas, mutant BRAF thyroid cancers are more refractory to BRAFi treatment as evidenced by a lower overall response rate [10, 22] – likely indicating an increased capacity for innate BRAFi resistance. Here, BRAF is linked to thyroid cancer.